![](https://endpts.com/wp-content/uploads/2022/08/Benjamin-Oakes-Scribe-Therapeutics-CEO.jpg)
Benjamin Oakes, Scribe Therapeutics CEO
Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact
Sanofi has inked another collaboration with its CRISPR partner Scribe Therapeutics as the duo seeks to create a newer, safer approach to tackling sickle cell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.